Formatech, through its Fillanthropy Program, will formulate and fill ViroMed’s VM206 vaccine targeting breast cancer. Formatech will donate the services required to aseptically fill and finish one lot of the vaccine to support ViroMed’s upcoming clinical trials. Formatech plans to complete the production run in March 2010. “We’re excited to have the opportunity to work with ViroMed on this program,” said Jeffrey Bernard, Formatech’s director of business development. “VM206 is a plasmid ...